ATE493389T1 - Chinoxalin-derivate die den von blutplättchen abstammenden wachstumsfaktor und/oder p56lck- tyrosinkinase hemmen - Google Patents

Chinoxalin-derivate die den von blutplättchen abstammenden wachstumsfaktor und/oder p56lck- tyrosinkinase hemmen

Info

Publication number
ATE493389T1
ATE493389T1 AT98926129T AT98926129T ATE493389T1 AT E493389 T1 ATE493389 T1 AT E493389T1 AT 98926129 T AT98926129 T AT 98926129T AT 98926129 T AT98926129 T AT 98926129T AT E493389 T1 ATE493389 T1 AT E493389T1
Authority
AT
Austria
Prior art keywords
platele
tyrosinkinase
p56lck
inhibit
growth factor
Prior art date
Application number
AT98926129T
Other languages
English (en)
Inventor
Alfred Spada
Wei He
Michael Myers
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE493389T1 publication Critical patent/ATE493389T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/54—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
AT98926129T 1997-05-28 1998-05-28 Chinoxalin-derivate die den von blutplättchen abstammenden wachstumsfaktor und/oder p56lck- tyrosinkinase hemmen ATE493389T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86445597A 1997-05-28 1997-05-28
US97261497A 1997-11-18 1997-11-18
PCT/US1998/011000 WO1998054157A1 (en) 1997-05-28 1998-05-28 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES

Publications (1)

Publication Number Publication Date
ATE493389T1 true ATE493389T1 (de) 2011-01-15

Family

ID=27127839

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98925022T ATE286886T1 (de) 1997-05-28 1998-05-28 Chinolin- und chinoxalin-verbindungen die den von blutplättchen abstammmenden wachstumsfaktor und/oder pdgf- und p56lck-tyrosin-kinase hemmen
AT98925041T ATE500233T1 (de) 1997-05-28 1998-05-28 Chinolin und chinoxalinverbindungen die den von blutplättchen abstammenden faktor und/oder p56ick-tyrosinkinase hemmen
AT98926129T ATE493389T1 (de) 1997-05-28 1998-05-28 Chinoxalin-derivate die den von blutplättchen abstammenden wachstumsfaktor und/oder p56lck- tyrosinkinase hemmen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT98925022T ATE286886T1 (de) 1997-05-28 1998-05-28 Chinolin- und chinoxalin-verbindungen die den von blutplättchen abstammmenden wachstumsfaktor und/oder pdgf- und p56lck-tyrosin-kinase hemmen
AT98925041T ATE500233T1 (de) 1997-05-28 1998-05-28 Chinolin und chinoxalinverbindungen die den von blutplättchen abstammenden faktor und/oder p56ick-tyrosinkinase hemmen

Country Status (25)

Country Link
EP (3) EP1001945B1 (de)
JP (3) JP2002500675A (de)
KR (2) KR100425638B1 (de)
CN (3) CN1140516C (de)
AP (3) AP1362A (de)
AT (3) ATE286886T1 (de)
AU (3) AU747026B2 (de)
BG (3) BG64419B1 (de)
BR (3) BR9809515A (de)
CA (3) CA2291728A1 (de)
CZ (3) CZ298490B6 (de)
DE (3) DE69842077D1 (de)
DK (1) DK0991628T3 (de)
EA (4) EA004103B1 (de)
ES (1) ES2235331T3 (de)
HU (2) HUP0004807A3 (de)
IL (3) IL133008A0 (de)
NO (3) NO323721B1 (de)
OA (3) OA11264A (de)
PL (3) PL194670B1 (de)
PT (1) PT991628E (de)
SI (1) SI0991628T1 (de)
SK (4) SK286084B6 (de)
UA (1) UA57790C2 (de)
WO (3) WO1998054158A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245760B1 (en) * 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6159978A (en) * 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AU747026B2 (en) * 1997-05-28 2002-05-09 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
MXPA03001306A (es) 2000-08-11 2003-10-15 Boehringer Ingelheim Pharma Compuestos heterociclicos utiles como inhibidores de las quinasas de tirosina.
ES2386828T3 (es) 2002-03-27 2012-08-31 Glaxo Group Limited Derivados de quinolina y su uso como ligandos 5-HT6
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SG149817A1 (en) 2004-01-16 2009-02-27 Wyeth Corp Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
EP2241557A1 (de) 2009-04-02 2010-10-20 Æterna Zentaris GmbH Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN101823998B (zh) * 2010-05-05 2015-03-25 江苏利田科技股份有限公司 一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
PT2624695E (pt) 2010-10-08 2015-12-01 Nivalis Therapeutics Inc Novos compostos de quinolina substituídos como inibidores de s-nitrosoglutationa redutase
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US8785643B2 (en) 2010-12-16 2014-07-22 N30 Pharmaceuticals, Inc. Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
IN2014KN02601A (de) 2012-04-24 2015-05-08 Vertex Pharma
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SMT202100687T1 (it) 2013-03-12 2022-01-10 Vertex Pharma Inibitori della dna-pk
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
ES2705342T3 (es) 2013-10-17 2019-03-22 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
WO2017044766A1 (en) 2015-09-10 2017-03-16 Nivalis Therapeutics, Inc. Solid forms of an s-nitrosoglutathione reductase inhibitor
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
EP3353164B1 (de) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl-substituierte 1,4-benzodiazepine und ihre anwendung in der krebsbehandlung
EP3518931A4 (de) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated Verfahren zur behandlung von krebs mit einer kombination aus dna-schädigenden substanzen und dna-pk-inhibitoren
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4323405A1 (de) 2021-04-12 2024-02-21 Incyte Corporation Kombinationstherapie mit einem fgfr-inhibitor und einem auf nectin-4 abzielenden mittel
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (de) * 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
US4888427A (en) * 1987-04-07 1989-12-19 University Of Florida Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
AU658646B2 (en) * 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
KR100224135B1 (ko) * 1993-01-28 1999-10-15 다께다 구니오 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
DE4426373A1 (de) * 1994-07-26 1996-02-01 Bayer Ag 3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung
CN1077107C (zh) * 1996-07-19 2002-01-02 武田药品工业株式会社 杂环化合物、其制备和用途
WO1998031228A1 (en) * 1997-01-21 1998-07-23 Nissan Chemical Industries, Ltd. Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing n-quinoxalylanilines
AU747026B2 (en) * 1997-05-28 2002-05-09 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

Also Published As

Publication number Publication date
EP1001946B1 (de) 2010-12-29
CZ415899A3 (cs) 2000-05-17
EP1001946A1 (de) 2000-05-24
SK157999A3 (en) 2000-06-12
SK286084B6 (sk) 2008-03-05
EA199901092A1 (ru) 2000-06-26
AP1554A (en) 2006-01-18
CA2291750A1 (en) 1998-12-03
UA57790C2 (uk) 2003-07-15
IL133009A0 (en) 2001-03-19
CZ298490B6 (cs) 2007-10-17
EP1001945B1 (de) 2011-03-02
EA004103B1 (ru) 2003-12-25
SK158099A3 (en) 2000-06-12
ATE286886T1 (de) 2005-01-15
CZ296845B6 (cs) 2006-07-12
PT991628E (pt) 2005-05-31
AU742739B2 (en) 2002-01-10
PL194670B1 (pl) 2007-06-29
DE69828607D1 (de) 2005-02-17
AU7707998A (en) 1998-12-30
PL337084A1 (en) 2000-07-31
AP9901710A0 (en) 1999-12-31
CN1261354A (zh) 2000-07-26
BR9809515A (pt) 2000-06-20
CN1140516C (zh) 2004-03-03
DE69828607T2 (de) 2006-01-05
NO995818L (no) 1999-11-26
BG64445B1 (en) 2005-02-28
KR20010013057A (ko) 2001-02-26
WO1998054156A1 (en) 1998-12-03
NO323720B1 (no) 2007-06-25
EA199901086A1 (ru) 2000-06-26
AU747026B2 (en) 2002-05-09
BR9809172A (pt) 2000-08-01
OA11222A (en) 2003-07-16
IL133007A0 (en) 2001-03-19
EA002600B1 (ru) 2002-06-27
NO995818D0 (no) 1999-11-26
IL133008A0 (en) 2001-03-19
KR100440756B1 (ko) 2004-07-21
WO1998054158A1 (en) 1998-12-03
BG64444B1 (en) 2005-02-28
PL195552B1 (pl) 2007-10-31
BG104006A (en) 2000-07-31
NO995817D0 (no) 1999-11-26
EP0991628B1 (de) 2005-01-12
AP9901709A0 (en) 1999-12-31
CN1280572A (zh) 2001-01-17
ATE500233T1 (de) 2011-03-15
AP1362A (en) 2005-01-19
EA007807B1 (ru) 2007-02-27
HUP0002084A2 (hu) 2000-10-28
AU751188C (en) 2005-06-30
CA2291774A1 (en) 1998-12-03
DK0991628T3 (da) 2005-05-17
DE69842077D1 (de) 2011-02-10
PL194980B1 (pl) 2007-07-31
SI0991628T1 (en) 2005-06-30
BG103965A (en) 2000-07-31
CA2291728A1 (en) 1998-12-03
NO995819L (no) 1999-11-26
PL337087A1 (en) 2000-07-31
CN1261353A (zh) 2000-07-26
OA11221A (en) 2003-07-16
AU7706298A (en) 1998-12-30
AP9901711A0 (en) 1999-12-31
EP0991628A4 (de) 2000-07-26
NO316377B1 (no) 2004-01-19
BR9809501A (pt) 2000-06-20
CZ418099A3 (cs) 2000-05-17
JP2002513417A (ja) 2002-05-08
SK158199A3 (en) 2000-06-12
HUP0002084A3 (en) 2000-12-28
CZ417999A3 (cs) 2000-05-17
HUP0004807A2 (hu) 2001-11-28
ES2235331T3 (es) 2005-07-01
BG103963A (en) 2000-07-31
EA199901090A1 (ru) 2000-08-28
EP1001946A4 (de) 2000-07-26
KR20010039512A (ko) 2001-05-15
NO995819D0 (no) 1999-11-26
JP2002500675A (ja) 2002-01-08
KR100425638B1 (ko) 2004-04-03
EA008136B1 (ru) 2007-04-27
IL133007A (en) 2005-06-19
HUP0004807A3 (en) 2001-12-28
HK1028042A1 (en) 2001-02-02
AU7803798A (en) 1998-12-30
EP1001945A4 (de) 2000-07-26
EP0991628A1 (de) 2000-04-12
NO323721B1 (no) 2007-06-25
AU751188B2 (en) 2002-08-08
NO995817L (no) 1999-11-26
AP1444A (en) 2005-07-18
EA200100575A1 (ru) 2002-02-28
DE69842151D1 (de) 2011-04-14
PL337086A1 (en) 2000-07-31
JP2002500676A (ja) 2002-01-08
CZ298521B6 (cs) 2007-10-24
BG64419B1 (bg) 2005-01-31
OA11264A (en) 2002-11-19
WO1998054157A1 (en) 1998-12-03
EP1001945A1 (de) 2000-05-24

Similar Documents

Publication Publication Date Title
ATE493389T1 (de) Chinoxalin-derivate die den von blutplättchen abstammenden wachstumsfaktor und/oder p56lck- tyrosinkinase hemmen
DE69738197D1 (de) Azolotriazine und pyrimidine
DE69911378D1 (de) Fluorierte ionomere und verwendung davon
ATE318257T1 (de) Trifluoromethylpyrrolcarboxamide und ihre anwendung als fungizide
DE69532671D1 (de) Endoprothesen und stents
DE59711118D1 (de) Spickeln, Zunehmen und Mindern
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
DE69719603D1 (de) Kosmetisches Haarwaschmittel und dessen Verwendung
DE69529026D1 (de) Trehalose, ihre Herstellung und ihre Verwendung
DE69904731D1 (de) Feinzerkleinerer und feinzerkleinerungsverfahren
DE60001735D1 (de) 1-aminotriazolo 4,3-a chinazolin-5-one und/oder -thione inhibitoren von phosphodiesterasen iv
DE69928233D1 (de) Durchflussaufnehmer und wandler
DE69917327D1 (de) 3,3-biarylpiperidin- und 3,3-biarylmorpholinderivate
DE68917352D1 (de) Trimethylolheptane und ihre Anwendung.
EP1071952A4 (de) I kappa b und verbessertes grün-fluoreszierendes protein
DE69916694D1 (de) 2-Hydroxy-5-methyl-hexan-3-on und 3-hydroxy-5-methyl-hexan-2-on
DE69932927D1 (de) Cabapenemderivate, ihre anwendung und ihre zwischenprodukte
DE19882580T1 (de) Schneidverfahren und Schneidöl
DE69432590D1 (de) 1,2,3,4-tetrahydrochinolin-2,3,4-trion-3 oder 4-oxime und ihre verwendung
EE9900019A (et) Asolotriasiinid ja -pürimidiinid
ATE282015T1 (de) Rheologieänderung und rheologiemodifiziermittel
DE69812256D1 (de) 7-propyl-benzodiosepin-3-one und dessen Verwendung in Parfümerie
DE69842206D1 (de) Echounterdrücker und echounterdrückungsverfahren
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
DE59708683D1 (de) Kupfer-Chrom-Titan-Silizium-Legierung und ihre Verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties